BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu X, Han R, Zhong Y, Weng N, Zhang A. Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma. Cancer Cell Int 2021;21:356. [PMID: 34233686 DOI: 10.1186/s12935-021-02072-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Chen X, Meng F, Jiang R. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:746976. [PMID: 34900692 DOI: 10.3389/fonc.2021.746976] [Reference Citation Analysis]
2 Wang L, Zhu Y, Zhang B, Wang X, Mo H, Jiao Y, Xu J, Huang J. Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy. Thorac Cancer 2022. [PMID: 35437954 DOI: 10.1111/1759-7714.14431] [Reference Citation Analysis]
3 Liu J, Shao J, Zhang C, Qin G, Liu J, Li M, Wu P, Zhao X, Zhang Y. Immuno-oncological role of 20S proteasome alpha-subunit 3 in aggravating the progression of esophageal squamous cell carcinoma. Eur J Immunol 2021. [PMID: 34755333 DOI: 10.1002/eji.202149441] [Reference Citation Analysis]
4 Wu X, Han R, Zhong Y, Weng N, Zhang A. Correction to: Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma. Cancer Cell Int 2021;21:693. [PMID: 34930249 DOI: 10.1186/s12935-021-02401-0] [Reference Citation Analysis]